Loading company…
Zephyrm develops and produces stem cell drugs for conditions affecting several body systems.
Founded in 2018, Zephyrm develops and produces stem cell drugs for conditions including meniscal injuries, respiratory diseases and ovarian insufficiency. It established a GMP production plant in Beijing in May 2019 and received clinical trial approval for a meniscal injury treatment in September 2021. In April 2023, it raised over CNY 200 million in Series B funding led by CCB Investment Funds Management. The company is based in Beijing, China.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in